期刊文献+

基于TCGA数据库分析COL10A1在HER2阳性乳腺癌中的表达及意义 被引量:3

EXPRESSION AND SIGNIFICANCE OF COL10A1 IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BREAST CANCER:AN ANALYSIS BASED ON TCGA DATABASE
下载PDF
导出
摘要 目的基于TCGA数据库分析COL10A1在人表皮生长因子受体2(HER2)阳性乳腺癌患者中的表达及其与患者预后的关系。方法基于GEPIA、Oncomine数据库分析COL10A1在乳腺癌中的差异性表达,UALCAN数据库分析COL10A1在不同乳腺癌病理亚型中的表达差异。通过Kaplan-Meier Plotter数据库分析COL10A1与乳腺癌患者临床预后的关系。结果GEPIA、Oncomine等生物学数据库分析显示,乳腺癌组织中COL10A1 mRNA表达水平显著高于正常组织(P<0.01);HER2过表达型乳腺癌组织中COL10A1表达高于三阴型,差异有统计学意义(P<0.05)。GEPIA和cBioPortal数据库分析显示,COL10A1与HER 2 mRNA表达水平呈正相关(P<0.01)。Kaplan-Meier Plotter在线数据库分析显示,HER2阳性乳腺癌组织中COL10A1高表达患者无复发生存率低(P<0.01)。结论COL10A1在HER2阳性乳腺癌组织中呈高表达,并与患者预后呈负相关,有望成为HER2阳性乳腺癌患者药物治疗的一个潜在靶点。 Objective To investigate the expression of COL10A1 in patients with human epidermal growth factor receptor 2(HER2)-positive breast cancer based on TCGA database and its association with prognosis.Methods The differential expression of COL10A1 in breast cancer was analyzed based on the GEPIA and Oncomine databases,and the UALCAN database was used to analyze the difference in the expression of COL10A1 in different subtypes of breast cancer.The Kaplan-Meier Plotter database was used to investigate the association between COL10A1 and clinical prognosis of breast cancer patients.Results The analysis based on the GEPIA and Oncomine biological databases showed that the mRNA expression of COL10A1 in breast cancer tissue was significantly higher than that in normal tissue(P<0.01),and the expression of COL10A1 in HER2-overexpressing breast cancer was significantly higher than that in triple-negative breast cancer(P<0.05).The GEPIA and cBioPortal databases showed a positive correlation between the mRNA expression of COL10A1 and HER2(P<0.01).The Kaplan-Meier Plotter database analysis indicated that the patients with HER2-positive breast cancer and high expression of COL10A1 had a low relapse-free survival rate(P<0.01).Conclusion Through the in-depth searching of database oncogene information,it is proposed that COL10A1 is highly expressed in HER-positive breast cancer tissue and is negatively correlated with patient’s prognosis,and therefore,it may become a potential target for pharmacotherapy for HER-positive breast cancer.
作者 蒋晗旭 王瀚冬 李义帅 于航 王川 刘月平 JIANG Hanxu;WANG Handong;LI Yishuai;YU Hang;WANG Chuan;LIU Yueping(Department of Pathology,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China)
出处 《精准医学杂志》 2020年第1期21-25,共5页 Journal of Precision Medicine
基金 国家自然科学基金资助项目(81770407) 河北医科大学大学生创新性实验计划项目(USIP2017113,USIP2018048)。
关键词 乳腺肿瘤 受体 erbB-2 COL 10 A 1基因 数据库 遗传学 预后 Breast neoplasms Receptor,ErbB-2 COL10A1 gene Databases,genetic Prognosis
  • 相关文献

参考文献6

二级参考文献58

  • 1姚云峰.结直肠癌的TNM分期[J].中国医学前沿杂志(电子版),2011,3(6):8-10. 被引量:28
  • 2杨学宁,吴一龙.实体瘤治疗疗效评价标准——RECIST[J].循证医学,2004,4(2):85-90. 被引量:1548
  • 3Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005,55(2):74-108.
  • 4Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005[J]. Cancer Epidemiol Biomarkers Prev, 2005,14(1):243-250.
  • 5Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000,406(6797):747-752.
  • 6Francis G, Beadle G, Thomas S, et al. Evaluation of estrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome[J]. Pathology, 2006,38(5): 391-398.
  • 7Mukai H. Treatment strategy for HER-2-positive breast cancer[J]. Int J Clin Oncol, 2010,15(4):335-340.
  • 8Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER-2 for metastatic breast cancer that overexpresses HER-2[J].N Engl J Med,2001,344(11): 783-792.
  • 9Extra JM, Cognetti F, Chan S, et al. Randomised phase II trial (M77001)of (Herceptin) plus docetaxel versus docetaxel alone,as first line therapy in patients with HER-2positive metastatic breast cancer[J]. J Clin Oncol, 2005,23(19):4265-4274.
  • 10von Minckwitz C, Zielinski C, Maartense E, et al. Capecitabine vs. capecitabine plus treastuzumab in patients with HER-2 positive metastatic breast cancer progressing during trastuzumab treatment the TBP phase III study (GBG 26 BIG 305)[J]. J Clin Oncol, 2009,27(12):1999-2006.

共引文献27

同被引文献14

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部